Complement C3 plays a central role in the activation of the complement system, and complement‐mediated muscle damage is at the heart of dysferlinopathy pathogenesis, suggesting that targeting the complement system may be a treatment for the disease [48]. The gene discussed is C3; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.